EchoGo Pro vs Eko Low Ejection Fraction Tool (ELEFT)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Ultromics
VS

AI Verdict

EchoGo Pro is designed for automating and enhancing the diagnosis of coronary artery disease through stress echocardiography analysis, providing detailed reports for cardiologists. In contrast, the Eko Low Ejection Fraction Tool (ELEFT) focuses on the early detection of low ejection fraction, an indicator of heart failure, by integrating AI with digital stethoscopes for use during routine physical exams. Therefore, EchoGo Pro is suited for advanced diagnostic imaging workflows, while ELEFT serves as a screening tool in primary care and general cardiology settings.

Choose EchoGo Pro if…

Choose EchoGo Pro if your cardiology department requires an advanced, AI-powered solution for automating stress echocardiography analysis to diagnose coronary artery disease efficiently. This tool is ideal for clinics seeking near-instant, accurate reports and seamless integration with existing PACS and clinical workflows, enhancing diagnostic throughput and precision.

View EchoGo Pro →

Choose Eko Low Ejection Fraction Tool (ELEFT) if…

Choose Eko Low Ejection Fraction Tool (ELEFT) if your practice needs a rapid, non-invasive screening tool for early detection of low ejection fraction during routine physical exams. This solution is best suited for clinicians in primary care or general cardiology looking to quickly identify patients at risk for heart failure using an integrated digital stethoscope.

View Eko Low Ejection Fraction Tool (ELEFT) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature EchoGo Pro Eko Low Ejection Fraction Tool (ELEFT)
Pricing Contact vendor for pricing Unknown
Deployment Cloud-based Unknown
BAA Available Yes AI-estimated Unknown
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoGo Pro

EchoGo Pro (Tool A) emphasizes a SaaS model requiring no software installation or extensive training, along with seamless integration into existing clinical workflows (DICOM, HL7) and vendor-neutral PACS compatibility. This highlights ease of deployment and integration for IT departments and specialists. While ELEFT (Tool B) offers quick results at the point of care, its reliance on specific Eko digital stethoscopes adds a hardware dependency.

Clinical Value

EchoGo Pro

EchoGo Pro (Tool A) is FDA-cleared and directly improves the diagnostic accuracy of coronary artery disease through automated stress echocardiography analysis, aiming to reduce misdiagnosis. ELEFT (Tool B) aids in the early detection of low ejection fraction, which is valuable for screening, but Tool A's direct impact on the accuracy of a definitive diagnostic test provides a strong, measurable clinical outcome.

Pricing & Value

EchoGo Pro

Both tools require contacting the vendor for pricing, indicating a lack of transparency. However, EchoGo Pro (Tool A) explicitly mentions the availability of reimbursement codes for related EchoGo products, which provides a clearer path for healthcare providers to justify the financial investment and achieve sustainability. ELEFT (Tool B) is part of an enterprise platform, which may imply a larger, less flexible pricing structure.

Enterprise Readiness

EchoGo Pro

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, essential for enterprise adoption. EchoGo Pro (Tool A) stands out with its explicit mention of being a 'vendor-neutral system, compatible with any PACS' and offering 'seamless integration with existing clinical workflows (DICOM, HL7)'. These features are crucial for integration into diverse and complex healthcare IT environments.

Innovation

Eko Low Ejection Fraction Tool (ELEFT)

Eko Low Ejection Fraction Tool (ELEFT) (Tool B) demonstrates greater innovation by integrating an AI algorithm with a common, non-invasive tool like a digital stethoscope for early detection of heart failure risk during routine physical exams. This approach brings advanced screening capabilities to the point of care in a broadly accessible manner, potentially transforming primary care. EchoGo Pro (Tool A) innovates within a specialized imaging domain, enhancing an existing diagnostic process.

Support & Docs

Eko Low Ejection Fraction Tool (ELEFT)

While neither tool's structured facts explicitly detail support or documentation, Eko Health (Tool B) provides readily accessible user manuals for its integrated Eko digital stethoscopes on its support website, which is a direct and tangible form of operational documentation for the end-user. Ultromics (Tool A) mentions dedicated customer support and training, but specific documentation resources are less apparent.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature EchoGo Pro Eko Low Ejection Fraction Tool (ELEFT)
Name EchoGo Pro Eko Low Ejection Fraction Tool (ELEFT)
Company Ultromics Eko Health
Primary Function Automates stress echocardiography analysis to improve the diagnosis of coronary artery disease. Aids clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.
Key Integration/Hardware Vendor-neutral system, compatible with any PACS; seamless integration with DICOM, HL7. Integrates with FDA-cleared Eko digital stethoscopes.
Result Speed Near-instant reports Approximately 15 seconds
Target Condition Coronary Artery Disease (CAD) Low ejection fraction (indicator of heart failure)

Videos

Demos, reviews, and walkthroughs featuring EchoGo Pro and Eko Low Ejection Fraction Tool (ELEFT).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

EchoGo Pro is designed to automate stress echocardiography analysis for the diagnosis of coronary artery disease (CAD), providing near-instant reports. In contrast, the Eko Low Ejection Fraction Tool (ELEFT) is an AI algorithm that aids in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.
EchoGo Pro analyzes echocardiogram images, specifically stress echo scans, to identify coronary artery disease. The Eko Low Ejection Fraction Tool integrates with Eko digital stethoscopes to analyze ECG and heart sound recordings for the detection of low ejection fraction.
EchoGo Pro is a vendor-neutral, cloud-based solution compatible with any PACS and integrates seamlessly using DICOM and HL7, requiring no software installation. ELEFT is cloud-based software that integrates with FDA-cleared Eko digital stethoscopes and is part of the SENSORAu2122 Cardiac Early Detection Platform.
EchoGo Pro is primarily intended for Cardiology, focusing on advanced echocardiography analysis. ELEFT is applicable to a broader range of specialties, including Cardiology, Family Medicine, and Internal Medicine, as it facilitates early screening during routine physical exams.
EchoGo Pro provides near-instant, comprehensive reports for automated identification of CAD, aiming to improve diagnostic accuracy and reduce misdiagnosis. ELEFT delivers results in approximately 15 seconds, aiding in the early identification of heart failure risk through low ejection fraction detection.
For EchoGo products, reimbursement codes are available, such as CPT 0932T for EchoGo Heart Failure and NTAP XXE2X19 for inpatient settings. ELEFT is part of Eko's SENSORAu2122 platform, which has a Category III CPT code (0962T) that became effective July 1, 2025, supporting reimbursement pathways for AI-enabled cardiac analysis.

Backers

Who funded each tool's parent company.

Eko Low Ejection Fraction Tool (ELEFT)

AI Tool Finder
AI-powered search. Results may not be comprehensive.